Background Neuropathic pain significantly reduces an individual's quality of life and places a significant economic burden on society. As such, many cost-effectiveness analyses (CEAs) have been published for treatments available for neuropathic pain. Objectives The primary objective of this systematic review was to provide a detailed summary of the estimates of costeffectiveness from published CEAs comparing available treatments for neuropathic pain. The secondary objectives were to identify the key drivers of cost-effectiveness and to assess the quality of published CEAs in neuropathic pain. Methods We searched Embase, MEDLINE, Cochrane CENTRAL and seven other databases to identify CEAs reporting the costs, health benefits (e.g., quality-adjusted life-years or disability-adjusted life-years) and summary statistics, such as incremental cost-effectiveness ratios, of treatments for neuropathic pain. We excluded studies reporting diseases other than neuropathic pain, those for which the full text was not available (e.g., conference abstracts), studies not written in English or not published in peer-reviewed journals, and narrative reviews, editorials and opinion papers. Titles and abstract reviews, full-text reviews, and data extraction were all performed by two independent reviewers, with disagreement resolved by a third reviewer. Mean costs, health benefits, and summary statistics were reported and qualitatively compared across studies, stratified by time horizon. Drivers of cost-effectiveness were assessed using reported one-way sensitivity analyses. The quality of all included studies was evaluated using the Tufts CEA Registry Quality Score and study reporting using the CHEERS (Consolidated Health Economic Evaluation Reporting Standards) checklist. Results A total of 22 studies were identified and included in this systematic review. Included studies were heterogeneous in the treatments compared, methodology and design, perspectives, and time horizons considered, making cross-study comparisons difficult. No single treatment was consistently the most cost-effective across all studies, but tricyclic antidepressants were the preferred treatment at a willingness-to-pay threshold of $US50,000 per quality-adjusted life-year in several studies with a short time horizon and a US payer perspective. Among the 14 studies reporting one-way sensitivity analyses, drivers of cost-effectiveness included utility values for health states and the likelihood of pain relief with treatment. The quality of the identified CEAs was moderate to high, and overall reporting largely met CHEERS recommendations. Limitations To assess drivers of cost-effectiveness and quality, we only included studies with the full text available and thus excluded some CEAs that reported cost-effectiveness results. The heterogeneity of the included studies meant that the study results could not be synthesized and comparison across studies was limited. Conclusions Though many pulished studies have evaluated the cost-effectiveness of treatments for neuropathic pain, significant heterogeneity between CEAs prevented synthesis of the results. Standardized methodology and improved reporting would allow for more reliable comparisons across studies.
Introduction
Neuropathic pain is a direct consequence of a lesion or disease that affects the somatosensory system [1] . Many conditions affect the nervous system and can cause neuropathic pain, including but not limited to diabetes, multiple sclerosis, trauma, HIV, cancer, trigeminal neuralgia and herpes zoster infections [1] . Of these, two that are frequently described in published literature are painful diabetic neuropathy (PDN)
Key Points for Decision Makers
This systematic review found significant differences in the design and reporting of cost-effectiveness analyses for treatments of neuropathic pain, which makes meaningful comparisons across studies difficult.
Tricyclic antidepressants were the preferred treatment in several studies when considering a short time horizon (1-12 months), a US payer perspective, and a willingness-to-pay threshold of $US50,000 per quality-adjusted life-year.
The primary drivers of cost-effectiveness were quality of life and the likelihood of pain relief with treatment, but only 14 of the 22 included studies performed the analyses necessary to assess this. the primary objective of this systematic literature review was to provide a detailed summary of the estimates of costeffectiveness from published CEAs comparing available oral or topical treatments for neuropathic pain, with a particular focus on PDN and PHN. Our secondary objectives were to identify the key drivers of cost-effectiveness and to assess the quality of published CEAs in neuropathic pain.
Methods
Our systematic review was conducted using a study protocol developed a priori and in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement recommendations (Table S1 in the Electronic Supplementary Material [ESM] ; study protocol available from authors upon request) [23] . Covidence© (Veritas Health Innovation) was used to manage all aspects of the review, data extraction, and quality assessment [24] .
Databases
We performed a literature search of ten databases in March and April of 2018 using prespecified search strategies tailored to each database. The databases included Embase, MEDLINE, Cochrane CENTRAL, Database of Abstracts of Reviews of Effects, CINAHL, Scopus, Web of Science, Academic Search Premier, EconLit, and the International Pharmaceutical Abstracts website.
Search Strategy
Our initial search strategy was created in Ovid MEDLINE and included medical subject headings (MeSH), keywords, or text included in the title or abstract of full-text original research articles, systematic reviews, or meta-analyses. Search terms included neuralgia, costs, cost analyses, and pharmacotherapy. Based on published guidelines for the treatment of neuropathic pain, we also included the following oral or topical treatment options in the search: pregabalin, gabapentin, duloxetine, venlafaxine, amitriptyline, desipramine, nortriptyline, tramadol, tapentadol, imipramine, carbamazepine, topiramate, oxycodone, morphine sulfate, capsaicin cream, and lidocaine [14, 25, 26] . Synonyms of all search terms were identified using the MeSH tree hierarchy, available from Ovid MEDLINE, and included in the search strategy. No language or date restrictions were initially enforced. Once the initial search strategy was created, it was then adapted to all other databases as needed. The final Ovid MEDLINE search strategy and the search strategies for all other included databases can be found in ESM 1. We de-duplicated all identified studies using EndNote ® (Clarivate Analytics) [27, 28] and Covidence© [24] . and post-herpetic neuralgia (PHN). PDN is a common complication of diabetes that increases in risk the longer patients live with diabetes, occurring in up to 20% of patients with diabetes [2] [3] [4] [5] [6] . PHN is the most common chronic complication of herpes zoster infection, occurring in 10-75% of cases [7] .
Neuropathic pain substantially reduces patients' healthrelated quality of life [8] . Specifically, patients with neuropathic pain report low levels of pain relief, low duration of response to treatment, depression, anxiety, poor sleep, negative mood and poor social functioning [9, 10] . Neuropathic pain also places a substantial economic burden both on healthcare resources, with direct medical costs estimated to exceed $US10 billion per year in the US [11] , and on societal costs with reduced productivity and employment [12] .
Several classes of medications are efficacious in treating neuropathic pain caused by PHN [13] and PDN [14] , including pregabalin, gabapentin, tricyclic antidepressants (TCAs), duloxetine, other anticonvulsants and topical medications. However, no clear consensus exists on the preferred treatments for patients with neuropathic pain [13, 14] . Given the high costs of treating and managing neuropathic pain, the substantial impact on quality of life, and the uncertainty surrounding optimal treatment, many cost-effectiveness analyses (CEAs) of treatments for PHN and PDN have been published.
Despite published recommendations surrounding best practices for CEA methods [15] [16] [17] [18] [19] and reporting [20] , published CEAs in neuropathic pain have differed significantly in both methodology (e.g., model type, setting, time horizon, and evaluated interventions) and reported results. Systematic reviews of CEAs for neuropathic pain treatments have included only those published before 2012 [1, 21] or those focused on identifying the strengths and limitations surrounding the data and modeling practices [22] . Therefore,
Eligibility Criteria
We included any type of CEA (i.e., trial based, model based, or observational cohort based) that evaluated the aforementioned treatments for neuropathic pain; diseases other than neuropathic pain were excluded. To improve the comparability of the reported results, we defined CEA as a study that reported both costs and standard health benefit outcomes, such as quality-adjusted life-years (QALYs), disability-adjusted life-years, or life-years gained. Studies were excluded if they did not report a summary statistic, such as an incremental cost-effectiveness ratio (ICER), net monetary benefit, or net health benefit. Studies reporting dominance or extended dominance in the results satisfied this criterion. As two of the aims of this paper were to identify key drivers of cost-effectiveness and to assess the quality of published CEAs, which likely could not be assessed without full reporting of the methods and results, we excluded studies if the abstract and/or full text was not available for review. We also excluded studies if they were not written in English, were not published in a peer-reviewed journal, or were narrative reviews, editorials, or opinion papers.
Review for Inclusion
The titles and abstracts of all studies identified from the literature searches were independently reviewed by two reviewers (NRN, JM, JM, and JK). All studies received either a "yes" or "no" vote to proceed to the full-text review by each reviewer. Studies with concordant "no" votes were excluded, and those with concordant "yes" votes underwent full-text review. Discordant votes were resolved by an independent third reviewer (BKB).
Full-text reviews of the included studies were independently performed by two reviewers (NRN, JM, JM, and JK) to determine final inclusion into our study. As with the title and abstract reviews, discordant votes were resolved by an independent third reviewer (NRN and BKB). For studies excluded during the full-text review, we specified and prioritized the reason for exclusion as (1) article full text unavailable, (2) article not written in English, (3) article did not evaluate cost and health benefit outcomes of interest, (4) article considered disease state other than neuropathic pain, and (5) article compared nonpharmacologic and pharmacologic interventions. Studies excluded in this final step were categorized under the highest priority exclusion criterion they met; thus, all reasons for exclusion were mutually exclusive.
Data Extraction
We extracted data from each study using the online Covidence© data collection tool, which was revised and approved by consensus from all authors after testing the data extraction process in two studies. Data elements extracted from each study are summarized in Table 1 . Similar to the review conducted to establish study eligibility, two reviewers independently extracted data from all included studies (NRN, JM, JM, JK, and BKB), with a third consolidating the extracted data into a single form (NRN and BKB). If different findings were obtained by the extracting reviewers, the consolidating author (NRN or BKB) referred to the original published text to resolve the conflict.
Additionally, we scored the quality of each study using the Tufts CEA Registry Quality Score and assessed the reporting in each study using the CHEERS (Consolidated Health Economic Evaluation Reporting Standards) checklist [20, 29, 30] . The Tufts CEA Registry Quality Score is a subjective rating of four components of CEA studies: (1) correct calculation of ICERs, (2) characterization of uncertainty, (3) specification of health economic assumptions, and (4) appropriate and explicit utility weight estimation [29] . Each reviewer that extracted data from a study also evaluated the quality of the study and assigned a score ranging from 1 (lowest quality) to 7 (highest quality) to each of the Tufts CEA Registry Quality Score components. These component scores were later averaged to provide an overall reviewer quality score for each study [29] . Once each reviewer score was obtained, both scores were averaged with those reported in the Tufts CEA Registry [30] (available through 2015) to assign a final quality score to each study. If the Tufts CEA Registry score was unavailable, only the reviewer scores were averaged.
The CHEERS checklist was developed by the International Society for Pharmacoeconomics and Outcomes Research to provide guidance to authors, editors, and peer reviewers regarding optimal reporting practices for economic evaluations. The CHEERS checklist comprises 24 items that should be reported across six domains in economic studies: (1) title and abstract, (2) introduction, (3) methods, (4) results, (5) discussion, and (6) "other." We identified the page numbers on which each of the 24 checklist items were reported in each study.
Data Analysis

Overall Summary
The number and proportion of CEAs published for each type of neuropathic pain (i.e., PDN only, PHN only, PDN and PHN, or other neuropathic pain) as well as the number and types of medications included in the studies were evaluated. Additional qualitative comparisons were made between the studies with regards to their overall model structure, model outcomes, and model time horizon.
Cost-Effectiveness Outcomes
Differences in the reported mean costs, mean effectiveness outcomes, and summary statistics (e.g., ICERs) were qualitatively assessed among the included studies, stratified by time horizon and type of neuropathic pain. ICERs were also re-calculated in the cost units reported by each paper relative to the next least costly, nondominated alternative. In addition, the results of the studies that reported probabilistic sensitivity analyses (PSAs) were summarized. Finally, the authors' cost-effectiveness conclusions regarding their modeled interventions were reported.
Drivers of Cost-Effectiveness
To identify key drivers of cost-effectiveness in neuropathic pain, we extracted the top five model parameters reported in the one-way sensitivity analyses of each study. We categorized model parameters, based on their descriptions, as follows: drug costs, other costs, utility, pain relief, adverse events, adherence, and medical care. Drug costs specifically included the cost of the medications being compared (e.g., pregabalin, gabapentin), and other costs included all other modeled costs (e.g., office visits, hospitalizations). The utility category included any utility or disutility included in the CEA (e.g., good pain relief, poor pain relief, adverse events). This was then further stratified based on whether or not the utility was associated with mild pain (or pain relief), moderate-to-severe pain (or lack of pain relief), or other/ unspecified utilities. Parameters categorized as pain relief were related to the effectiveness measure used by each study to assess whether or not patients experienced pain relief as a result of a medication (e.g., pain score reductions, probability of good pain relief). The adverse events and adherence categories included model probabilities for each component. Finally, medical care included variables directly related to nonpharmacologic, medical care (e.g., office visit frequency, nurse/physician time). Once all model parameters were categorized, we then quantified (1) the total number of times each category was reported and (2) the total number of studies reporting each category at least once.
Quality Assessment
The average Tufts CEA Registry Quality Score, as well as the proportion of CEAs with a score < 5 versus ≥ 5, were reported. We qualitatively assessed the reasons for low scores to help determine potential areas for improvement. Finally, the number of items on the CHEERS checklist not included in the articles were quantified, and trends in CEA reporting were described. Name of all modeled/included treatments 8 Dose, frequency, and duration of treatment for each intervention 9
Outcomes assessed (e.g., QALYs, DALYs, LYs, adverse events, pain, type of costs, year in which costs were reported, type of effectiveness, etc.) 10 Sources for probabilities, utilities, costs, and baseline characteristics, if applicable (e.g., published literature, national estimates, local estimates, primary data analysis, or other) 11 Reported methods for pooling data on probabilities, utilities, costs, and baseline characteristics, if applicable 12 Types of distributions used for uncertainty of probabilities, utilities, costs, and baseline characteristics, if applicable 13 Estimated mean costs, mean effectiveness (e.g., QALYs, DALYs) for each treatment considered and ICERs or NMBs for each comparison made, including results of dominant or dominated treatment 14 Up to the top five variables reported as having the largest impact in one-way sensitivity analyses or in a tornado diagram 15 Results of probabilistic sensitivity analyses, (i.e., reported mean costs, QALYs, and ICER or NMB, probability of being cost-effective at reported or country-specific cost-per-QALY willingness-to-pay thresholds)
Results
In total, 2323 records were identified from the ten databases. After deduplication, we screened the titles and abstracts of 1557 records ( Fig. 1 ). Of these, 68 records underwent full-text review. After excluding full-text articles that did not meet our eligibility criteria, 22 studies were included . Deviations from our a priori study protocol are described in ESM 1.
Overall Summary
Details of all included studies can be found in Table 2 and Table S2 in ESM 1. Most of the studies evaluated the costeffectiveness of treatment options in patients with PDN only (N = 6) [34-37, 42, 47] , PHN only (N = 6), [32, 40, 44, 46, 49, 51] , or either PDN or PHN (N = 4) [33, 38, 50, 52] ; in only one of these studies were results stratified according to the type of neuropathic pain [52] . The remainder of the studies evaluated broader patient populations that included some combination of PDN, PHN, and other types of neuropathies (N = 6) [31, 39, 41, 43, 45, 48] . The majority of included studies were analyzed using a payer perspective, but some used a societal perspective either alone (N = 1) [51] or alongside (N = 3) [41, 42, 48] a payer perspective. Studies were performed from countries around the world, with seven from the USA [32, 35, 36, 38, 46, 47, 51] , four from the UK [34, 40, 43, 49] , three from Spain [41, 42, 50] , two from Belgium [31, 39] , and one each from Canada [52] , Germany [44] , Greece [33] , Mexico [37] , Scotland [45] , and Sweden [48] ( Table 2 [34, 35, 40, 44, 49] , and the remainder looking at ≥ 1-year time horizons. Of the latter, only one study evaluated a lifetime time horizon [51] . All studies estimated mean costs and QALYs for each treatment, with the exception of one study that reported mean utility over 1 month, which we converted to QALYs [38] . The way in which treatment pain relief was defined and applied in the models was largely obtained from published literature and differed widely across the included studies. Definitions ranged from the probability of experiencing good pain relief on different pain scales using different thresholds through to pain score changes over time. Finally, a minority of studies explicitly included patient adherence to treatment in their models (Table S2 Table 3 summarizes the reported mean costs and QALYs for all included studies, stratified by time horizon as ≤ 3 months, 6 months, and ≥ 1 year. Despite being the most comparable because of the number of studies included, the ICERs reported by each of the studies with a ≤ 3-month time horizon varied greatly. This was due in part to differences in currencies and healthcare delivery and payment systems between countries.
Cost-Effectiveness Outcomes
In studies with a ≤ 3-month time horizon, all treatments were dominated by another in at least one analysis, except for duloxetine and TCAs (i.e., amitriptyline and desipramine). Duloxetine was only included in two studies in this time-horizon stratum, both of which reported it to be costeffective compared with their respective willingness-to-pay (WTP) thresholds [37, 47] . Similar trends were observed in the 6-month time horizon (ICERs ranged from dominated and extendedly dominated to about €3000 per QALY gained) and ≥ 1-year time horizon strata (ICERs ranged from dominated and extendedly dominated to Swedish krona (SEK)126,000 per QALY gained). However, additional medication types were included in longer time horizon analyses (e.g., lidocaine plaster, capsaicin patch, tramadol). In most of the studies across all time horizon strata, TCAs or "usual care" was the least costly alternative, though effectiveness estimates varied drastically.
We excluded two studies [34, 51] from all of the time horizon strata, as they evaluated treatment sequences rather than single interventions. Therefore, the estimates for mean costs and QALYs for these two studies incorporate prespecified medication switches over time and cannot be adequately compared with the rest of the included studies.
Ultimately, differences in study perspectives, model structures, and assumptions meant that no single treatment emerged as the most cost-effective across all studies. However, in four of the seven studies performed from a US payer perspective, TCAs were the preferred treatment option at a WTP threshold of $US50,000 per QALY [32, 38, 46, 47] . All four of these studies compared three or more treatments, allowing for greater cross-study comparability. However, three of the four studies had time horizons ≤3 months [38, 46, 47] , and the longer time horizon studies that included TCAs had mixed results [32, 36] . Though multiple UK studies were also performed, they largely compared only two treatments, making comparisons and conclusions uncertain. Similarly, trends in the cost-effectiveness of treatments for neuropathic pain in other countries could not be reliably assessed because of the low number of studies published in each.
Of the 22 included studies, only four studies did not carry out and report results of a PSA: two with a ≤ 3-month time horizon [33, 52] and two with a ≥ 1-year time horizon [31, 43] . Overall, the results of the PSAs supported the authors' main conclusions listed in Table 3 , but-as expected-the conclusions of several studies changed as the WTP threshold increased.
Drivers of Cost-Effectiveness
Only 14 studies reported the results of one-way sensitivity analyses [33-37, 40-42, 44-47, 50] . However, several studies did not perform comprehensive one-way sensitivity analyses on all model parameters (e.g., included all parameters except resource utilization or drug costs) or only performed one-way sensitivity or scenario analyses altering specific input parameters. Based on this finding, regardless Carlos et al. [37] (1) GAB (generic) Liedgens et al. [44] (1 Bellows et al. [36] (1 Gordon et al. [43] (1 Year not explicitly reported in the study, but inferred to be 2010 based on when the article was submitted for consideration for publication of whether comprehensive one-way sensitivity analyses were performed, we examined the reported input parameters from each study with the greatest influence on model outcomes when we assessed the drivers of cost-effectiveness. Many studies did not report more than a few parameters, and only 63 of the potential 70 most influential parameters (14 studies multiplied by five potential model parameters each) were reported and available for evaluation. Among these 14 studies, the top five most influential model parameters included utility values in 13 studies [33-37, 40-42, 44, 46-48, 50] , pain relief in seven studies [34, 35, 37, [45] [46] [47] [48] , drug costs in four studies [33, 34, 41, 42] , and medical care in four studies [33, 41, 42, 45] (Fig. 2) . When considering the total number of times each model parameter category was reported as being in the top five most influential parameters, the top three categories were utility (N = 21), pain relief (N = 12), and other costs (N = 7). When stratifying utility by type, utility associated with mild pain (or pain relief) and moderate-to-severe pain (or poor pain relief) were reported equally (N = 6 for each), with other/unspecified utilities reported nine times ( Fig. 2 and Table S3 in the ESM).
Quality Assessment
For all included studies, the median Tufts CEA Registry Quality Score reported in the online Tufts CEA Registry was 5.0 (IQR 4.5-5.5) (N = 19; Table S4 in the ESM) [31-35, 37-47, 49, 50, 52] . After including our reviewer scores, the median score increased to 5.4 (IQR 4.8-5.8) (Fig. 3) . Overall, these scores indicate moderate-to-high quality for the included CEA studies. Commonly reported reasons for lower scores amongst our reviewers included (1) ICER calculations versus a treatment of interest rather than the next least costly, nondominated alternative, which is common practice; (2) subpar characterization and reporting of sensitivity analyses; and (3) concerns surrounding the source and application of utility values.
Eight studies had an average Tufts CEA Registry Quality Score < 5.0 [31, 32, 38, 40-42, 49, 52] , and 14 had an average score ≥ 5 [33-37, 39, 43-48, 50, 51] . Overall, there did not appear to be any differentiating features (e.g., time horizon, modeled treatments, treatments considered costeffective) to characterize the studies when stratifying on the Tuft's CEA Registry Quality Score. However, we found that a greater proportion of studies with a score ≥ 5 were 
Frequency
Total Count Reported At Least Once
Subset of "Any Utility" Fig. 2 Frequency of one-way sensitivity analysis model parameters by category. This figure highlights the categories of input parameters to which cost-effectiveness estimates were most sensitive in the oneway sensitivity analyses of the included studies. We only considered up to five of the most influential parameters on the model outcomes and assessed the (1) total number of times the category was reported and (2) number of times each category was reported at least once.
Only 14 included studies performed one-way sensitivity analyses, not all of them performed a comprehensive set of sensitivity analyses (i.e., several only examined scenarios varying a subset of model parameters), and many did not report more than a few variables (i.e., only 63 of the potential 70 most influential variables [five variables × 14 studies] were reported) published in or after 2010 (57.1%) compared with those with a score < 5 (25.0%). This could reflect greater efforts by professional organizations and guideline committees to increase transparency and standardization of CEA reporting. Also, while the majority of studies overall were sponsored by industry, we found a lower percentage with a score ≥ 5 (64.3%) were sponsored than those with a score < 5 (87.5%). Nonetheless, the proportion of studies that adequately followed the CHEERS criteria for CEA reporting was high (Table S5 and Fig. S1 in the ESM). Overall, all included studies met at least 20 of the 24 items on the CHEERS criteria checklist. The least commonly reported item across the studies was "results-characterizing heterogeneity," followed by "methods-discount rate" and "methods-setting and location." Though all studies met the "methods-characterizing uncertainty" criterion by assessing uncertainty to some extent, few studies assessed all aspects of uncertainty. For example, parameter uncertainty was performed and reported using one-way sensitivity analyses by only 14 studies, PSAs by 18 studies [32, [34] [35] [36] [37] [38] [39] [40] [41] [42] [44] [45] [46] [47] [48] [49] [50] [51] , and both of these by 12 studies [34-37, 40-42, 44-48] . Two studies only carried out scenario analyses rather than one-way sensitivity analyses or PSAs [43, 52] .
Discussion
In this systematic review, we identified and included 22 published studies that evaluated the cost-effectiveness of treatments for neuropathic pain, particularly PDN and PHN. Heterogeneity was high among included studies with regard to the treatments compared, perspectives, methodology used to design and construct the models, assumptions made, and time horizons considered. While no single treatment was identified as the most cost-effective across all studies, those performed over a short time horizon (≤ 3 months) from a US payer perspective suggested that TCAs, because of their relatively low costs, may be the preferred treatment at a WTP threshold of $US50,000 per QALY. However, mixed results from CEAs including TCAs over longer time horizons increase the uncertainty of this conclusion. In addition, we identified utility values and probability of pain relief as key drivers of the cost-effectiveness of treatments for neuropathic pain. However, only 14 of the 22 included studies performed the necessary one-way sensitivity analyses to determine drivers of cost-effectiveness. Finally, we assessed the quality of the CEAs, with regards to both methodology (i.e., Tufts CEA Registry Quality Score) and compliance with published reporting standards (i.e., CHEERS). Overall, the CEAs included in this study were moderate-to-high quality, with a median Tufts CEA Registry Quality Score of 5.4 (out of 7 points, with higher scores indicating higher quality). In addition, the vast majority of CEAs reported at least 20 of the 24 items on the CHEERS checklist.
The number of published systematic reviews of CEAs in neuropathic pain are limited. The first, published by Darba et al. [21] reviewed the literature of pregabalin use in the treatment of neuropathic pain, anxiety disorder, and epilepsy. However, our results are not directly comparable as their review (1) included only three CEAs of pregabalin for neuropathic pain, all of which were identified and included in our study, (2) focused solely on pregabalin, and (3) included study designs other than CEAs. The second, by Critchlow et al. [22] , was a systematic review that examined the strengths and limitations of published CEAs and provided recommendations for future CEAs. As our updated literature search was focused on peer-reviewed publications, we identified all but one of the CEAs identified by Critchlow et al. [22] -the 2013 UK National Institute for Health and Care Excellence (NICE) pharmacological management of neuropathic pain guideline (discussed below) [26] . However, we included three additional CEAs [36, 44, 45] . Overall, Critchlow et al. [22] advocated for more research of health-related quality-of-life outcomes, costs, resource utilization, and adverse events associated with treatments for neuropathic pain [22] . They also encouraged the use of pain scores rather than relative risks in modeling pain relief, emphasized the need for more transparency in reporting model inputs, and highlighted the importance of carrying out and reporting the results of sensitivity analyses [22] . Finally, the 2013 NICE pharmacological management of neuropathic pain guideline included a systematic review of neuropathic pain CEAs [26] . While we included all of the CEAs identified by NICE, a direct comparison to our study is difficult as NICE did not further report results of their systematic review. However, NICE developed a decision tree model to assess the cost-effectiveness of 16 treatment options for neuropathic pain from a UK National Health Service perspective over 5 months. In their analysis, only placebo, amitriptyline, gabapentin, and capsaicin cream were not dominated [26] . However, the short time horizon, methodological differences, and lack of one-way sensitivity analysis means their CEA only added to the heterogeneity of neuropathic pain CEAs and did not alter our overall results and conclusions.
To our knowledge, our study is the first systematic review to evaluate the quality of published CEAs and identify key drivers of the cost-effectiveness of treatments for neuropathic pain. The heterogeneity of the identified studies meant that no single treatment was found to be more cost-effective than all others. Therefore, the individual characteristics of the published CEAs (i.e., perspective, time horizon, patient population, and treatment options) must be considered when assessing the cost-effectiveness of treatment options for neuropathic pain. However, the results of our study echo those reported by Critchlow et al. [22] . Specifically, our results highlight the continued need for increased transparency in CEA reporting and for the assessment of model uncertainty through sensitivity analyses. In addition, our identified key drivers of cost-effectiveness-utility values and probability of pain relief-highlight the need to ensure adequate inputs for the modeled patient population, as well as the assessment of uncertainty with these specific parameters. Finally, diagnosing and managing neuropathic pain in clinical settings is challenging because of the lack of diagnostic certainty, patient and provider behaviors, comorbid mental health concerns, and use of neuropathic pain treatments for other indications [14, 53, 54] . While CEAs are designed to mirror clinical practice, translating the results to these settings may be challenging as inputs are often derived from randomized controlled trials, which may lack generalizability. We found only a minority of studies included patient adherence to treatment; broader inclusion of patient and provider behaviors in neuropathic pain CEAs may improve real-world cost-effectiveness estimates.
Our study has several limitations that must be considered. First, to limit the scope of our search, we only considered medications with either topical or oral administration routes. Some studies did not meet our eligibility criteria but evaluated uncommon interventions that may be used as last-line treatments for neuropathic pain, such as intravenous immunoglobulin and thoracic transforaminal epidural steroid injections. In addition, we excluded studies for which the full text was unavailable (e.g., conference abstracts), which may have limited our study findings. However, abstracts are short and often provide limited data on the study's methodology, which would have made it difficult for us to achieve our study objectives of assessing quality and identifying drivers of cost-effectiveness. Next, it was difficult to account for the significant differences between healthcare delivery and payment systems between countries when assessing the cost-effectiveness of neuropathic pain treatments. Our analysis was also unable to account for changes in the generic availability of medications over time or other healthcare innovations that affect pricing. Therefore, we were unable to quantitatively synthesize the results of all studies to provide contemporary estimates of the cost-effectiveness of neuropathic pain treatments. Future studies should attempt to carry out such a synthesis analysis if more methodologically uniform CEAs are published.
Conclusions
The results of our systematic review highlight the heterogeneity present in currently published CEAs of treatment options for neuropathic pain. Though the overall quality of the publications is moderate to high, and their reporting is generally acceptable, comprehensive conducting and reporting of sensitivity analyses is lacking. We identified that the key drivers of cost-effectiveness were utility values and probability of pain relief, but making comparisons and generalizations across studies was difficult, as concerns about utility values were a common reason for lower-quality scores, and a wide range of pain relief definitions was applied across the CEAs. As discussed in other published work, CEAs in neuropathic pain could benefit from more standardized methodology and improved reporting to allow for easier and more reliable comparisons across studies. Standardizing CEA modeling approaches will allow for the synthesis of cost-effectiveness estimates in future research.
